Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Harvard Apparatus Regenerative Technology ( (HRGN) ).
On June 20, 2025, Harvard Apparatus Regenerative Technology held its 2025 Annual Meeting of Stockholders, where key proposals were voted on by shareholders. The meeting resulted in the election of two directors for a three-year term, the ratification of CBIZ CPAs P.C. as the independent accounting firm, and the approval of several amendments including the declassification of directors and a reverse stock split. These decisions are expected to impact the company’s governance structure and financial strategy moving forward.
Spark’s Take on HRGN Stock
According to Spark, TipRanks’ AI Analyst, HRGN is a Underperform.
HRGN faces significant financial challenges, with persistent net losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation is unattractive with a negative P/E ratio. The lack of positive earnings call updates contributes to a low overall stock score.
To see Spark’s full report on HRGN stock, click here.
More about Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology, Inc. operates in the regenerative medicine industry, focusing on developing and commercializing innovative medical products for tissue regeneration and repair.
Average Trading Volume: 2,359
Technical Sentiment Signal: Sell
Current Market Cap: $25.31M
Find detailed analytics on HRGN stock on TipRanks’ Stock Analysis page.